Lifeboat Foundation

In a paper published in the July 31 issue of Science Translational Medicine, researchers at Fred Hutchinson Cancer Research Center used CRISPR-Cas9 to edit long-lived blood stem cells to reverse the clinical symptoms observed with several blood disorders, including sickle cell disease and beta-thalassemia.

It’s the first time that scientists have specifically edited the genetic makeup of a specialized subset of adult blood stem cells that are the source of all cells in the blood and immune system.

The proof-of-principle study suggests that efficient modification of targeted stem cells could reduce the costs of gene-editing treatments for blood disorders and other diseases while decreasing the risks of unwanted effects that can occur with a less discriminating approach.

FAIRY-SIZED astronauts will become humanity’s weapon of choice when it comes to exploring the universe.

That’s the shock claim made by one expert, who reckons by the end of the century we’ll be creating tiny people with wings to travel to new worlds for us.

Dr Ian Pearson, a “futurologist” – someone who specialises in predicting future tech trends – says we’ll soon be able to genetically engineer folk of all shapes and sizes.

Mr. Epstein’s vision reflected his longstanding fascination with what has become known as transhumanism: the science of improving the human population through technologies like genetic engineering and artificial intelligence. Critics have likened transhumanism to a modern-day version of eugenics, the discredited field of improving the human race through controlled breeding.

Mr. Epstein, the accused sex trafficker, was fascinated by eugenics. He told scientists and others of his vision of using his New Mexico ranch to impregnate women.

Working with mouse and human tissue, Johns Hopkins Medicine researchers report new evidence that a protein pumped out of some—but not all—populations of “helper” cells in the brain, called astrocytes, plays a specific role in directing the formation of connections among neurons needed for learning and forming new memories.

Using mice genetically engineered and bred with fewer such connections, the researchers conducted proof-of-concept experiments that show they could deliver corrective proteins via nanoparticles to replace the missing protein needed for “road repairs” on the defective neural highway.

Since such connective networks are lost or damaged by neurodegenerative diseases such as Alzheimer’s or certain types of intellectual disability, such as Norrie disease, the researchers say their findings advance efforts to regrow and repair the networks and potentially restore normal brain function.

Victoria Gray, 34, of Forest, Miss., has volunteered for one of the most anticipated medical experiments in decades: the first attempt to use the gene-editing technique CRISPR to treat a genetic disorder in the U.S. Meredith Rizzo/NPR hide caption.

But getting human cells to grow in another species is not easy. Nakauchi and colleagues announced at the 2018 American Association for the Advancement of Science meeting in Austin, Texas that they had put human iPS cells into sheep embryos that had been engineered not to produce a pancreas. But the hybrid embryos, grown for 28 days, contained very few human cells, and nothing resembling organs. This is probably because of the genetic distance between humans and sheep, says Nakauchi.

The research could eventually lead to new sources of organs for transplant, but ethical and technical hurdles need to be overcome.

Gene editing is advancing at a faster pace than most of us can keep up with. One significant recent announcement was gene editing tool CRISPR’s application to non-genetic diseases thanks to a new ability to edit single letters in RNA.

Even as CRISPR reaches milestones like this, scientists continue to find new uses for it to treat genetic conditions. The next one that will hit clinics is a CRISPR treatment for a form of blindness called Leber congenital amaurosis (LCA).

Having been approved by the FDA in December, the treatment will be the first of its kind to be trialed in the US.

In a milestone for forensic criminal investigators, a convicted killer received two life sentences on Wednesday for a 1987 double slaying after becoming the first person arrested through genetic genealogy to be found guilty at trial.

“The conviction and sentencing of William Earl Talbott II marks a new era for the use genetic genealogy for identifying violent criminals since it has now been tested and tried in a court of law,” geneology expert CeCe Moore told ABC News.

William Earl Talbott II was arrested in May 2018 and charged with aggravated murder for the Washington state cold case killings of 20-year-old Jay Cook and 18-year-old Tanya Van Cuylenborg, authorities said. A jury found Talbott guilty last month.